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Abstract
Background: Prevalence rates for long-term injection drug users in some localities surpass 60% for HIV and 80% for
HCV. We describe methods for developing grounded hypotheses about how some injectors avoid infection with either
virus.
Methods: Subjects: 25 drug injectors who have injected drugs 8 – 15 years in New York City. 17 remain without
antibody to either HIV or HCV; 3 are double-positives; and 5 are positive for HCV but not HIV. "Staying Safe"
methodology compares serostatus groups using detailed biographical timelines and narratives; and information about
how subjects maintain access to physical resources and social support; their strategies and tactics to remain safe; how
they handle problems of addiction and demands by drug dealers and other drug users; and how their behaviors and
strategies do or do not become socially-embedded practices. Grounded theory and life-history analysis techniques
compare and contrast doubly-uninfected with those infected with both viruses or only with HCV.
Results: Themes and initial hypotheses emerging from analyses included two master hypotheses that, if confirmed,
should help shape preventive interventions: 1) Staying uninfected is not simply a question of social structure or social
position. It involves agency by drug injectors, including sustained hard work and adaptation to changing circumstances.
2) Multiple intentionalities contribute to remaining uninfected. These conscious goals include balancing one's need for
drugs and one's income; developing ways to avoid drug withdrawal sickness; avoiding situations where other drug users
importune you to share drugs; and avoiding HIV (and perhaps HCV) infection. Thus, focusing on a single goal in
prevention might be sub-optimal.
Other hypotheses specify mechanisms of enacting these intentionalities. One example is finding ways to avoid extreme
social ostracism.
Conclusion: We have identified strategies and tactics that some doubly-uninfected IDUs have developed to stay safe.
Staying Safe methodology develops grounded hypotheses. These can be tested through cohort studies of incidence and
prevention trials of hypothesis-based programs to help drug injectors make their injection and sexual careers safer for
themselves and others. This positive deviance control-case life history method might be used to study avoiding other
infections like genital herpes among sex workers.
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Background
Highly-infectious endemic sexually-transmitted or
parenterally-transmitted diseases typically infect large per-
centages of susceptibles within a few years of their begin-
ning to have sex or to inject drugs. This is true of hepatitis
C for illicit drug injectors [1], human papillomavirus for
sexually active people [2], and herpes simplex, Type 2, for
commercial sex workers [3].
Epidemiology has developed many methods to determine
the risk factors for becoming infected. For hepatitis C
among drug injectors, for example, these include the
number of years a person has injected drugs, receptive
syringe sharing, and sharing the "cookers" in which drug
mixtures are prepared and from which the solution is
extracted by users' syringes [4-12]
For these highly-infectious diseases, however, knowing
the risk factors may not be adequate to suggest effective
prevention methods. For endemic hepatitis C, for exam-
ple, the combination of the infectivity of the virus, the
high prevalence of infectious people in drug injector pop-
ulations, and the socially- or personally-created difficul-
ties of avoiding all risk combine to render prevention only
marginally effective. Thus, in spite of a large and well-
developed set of programs to prevent the spread of HIV
among drug injectors, among people who had been
injecting drugs between eight and fifteen years, approxi-
mately 70% in both Sydney, Australia, and London, Eng-
land, were infected by hepatitis C [13]. Most researchers
and public health workers in the field believe that there is
a dire need for new approaches to prevention. In the
absence of an effective preventive vaccine, or perhaps even
after one is developed if it proves as difficult to arrange
vaccination of injectors against hepatitis C as it has proved
to be for hepatitis B [14,15], such prevention will have to
be sociobehavioral.
One approach might be to ask how the long-term injec-
tors who have remained uninfected with hepatitis C have
done so. Current research methods, however, do not pro-
vide a way to study how these uninfected injectors (or par-
allel uninfected members of other populations, such as
long-term sex workers who have avoided genital herpes)
have managed to stay safe. (See the beginning of the
Methods section for discussion of how potential differ-
ences in biological susceptibility need to be taken into
account.)
Determining how some people stay uninfected over the
long term is not just a question of reversing the signs in a
risk factor equation. This is because what we need to learn
is how and why the uninfected people were able to avoid
high-risk situations and behaviors sufficiently well so as
not to have become infected (See Figure 1).
Thus, a risk factor study focuses on what behaviors, part-
ners, personal biological factors, and environmental fac-
tors come together to lead to one or more short-term
events in which a virus is transmitted to and infects a sub-
ject. To understand long-term non-infection, however, we
must study what patterns of long-term behavior and
social interaction, and thus what strategies and practices
of risk-avoidance, differentiate IDUs who are infected
from those who are not infected.
Even the terminology we need to address this issue may
seem unusual to some readers. Strategies are purposeful
and planned patterns of behaviors that are meant to attain
one or more goals. This can get complicated. Strategies to
prevent infection are one thing; but other strategies, such
Hypothesized relationship between long-term risk avoidance and short-term risk for HIV or HCV infection Figure 1
Hypothesized relationship between long-term risk avoidance and short-term risk for HIV or HCV infection
Minimizes frequency 
of high-risk events 
Long-term risk-avoidance 
x Protective practices 
x Protective strategies 
x Indigenous protective tactics 
x Avoid or overcome obstacles to reduced 
risk (for example, how to convince 
sexual or injection partners who want to 
engage in unsafe behaviors to act more 
safely; controlling addiction that might 
make it harder to stay safe; changing 
the norms of one’s social network; 
helping sex partners avoid or cure STIs) 
x Engage in other forms of goal-directed 
action that reduce the probability of 
being in high-risk situations 
  Moments of risk 
x Behaviors 
x Risk  networks 
x  Settings such as shooting galleries 
or group sex events (for HIV) 
x  STIs or other sources of high 
susceptibility to infection (for HIV) 
x  Risk behaviors with partners when 
they are highly’ infective BMC Public Health 2008, 8:94 http://www.biomedcentral.com/1471-2458/8/94
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as strategies to maintain some control over one's addic-
tion, may be equally or more important in long-term pre-
vention of HIV and HCV. Practices are socially-embedded
and socially-meaningful behaviors or sets of behaviors.
Although momentary acts or behaviors can lead to getting
infected (or infecting someone else), socially-embedded
and socially-meaningful patterns of behavior (such as try-
ing to maintain respectability in the eyes either of non-
user relatives or of "righteous dope fiends") involve long-
term maintenance of safer (or riskier) behaviors.
We present here a methodology through which to dis-
cover grounded hypotheses [16,17]. by investigating dif-
ferences between those who stay uninfected over the long
haul and those who become infected. This methodology
can, with some margin of error, uncover and develop
hypotheses about what circumstances, practices and strat-
egies protect people from infection by comparing out-
wardly-high-risk people who are not infected with those
who are infected–with the emphasis being to study how
the uninfected controls differ from the infected cases. This
requires that we study people who have embodied these
practices and strategies for a long enough time for the
oddities of chance (as expressed in the probabilistic
nature of viral transmission and of having a partner who
is infectious) to even out.
Positive Deviance Research
Researchers in child nutrition in developing countries
have found that, even in communities where malnutrition
is common, some children are not malnourished [18,19]
Using the concept of "positive deviance," they study the
practices and other characteristics of the few families
whose children are well-nourished even though their
access to resources was similar to that of other families. In
the words of a summary document about this approach,
these "characteristics may be behavioral, social, psycho-
logical, or physiological [20]." The method is generally
applied to high-risk circumstances–like communities
with high rates of malnourished children, or IDU commu-
nities where HCV and HIV are highly prevalent–and
"focuses on identifying sources and pathways of natural
immunity or adaptive resistance." The summary docu-
ment [20] adds, "positive-deviance studies tend to require
complicated designs and analyses, because many psycho-
logical and behavioral factors contribute to resistance."
We would add that many social and environmental fac-
tors must also be considered. The concept of positive devi-
ance seems to overlap with other concepts such as
resilience, hardiness, well-being, and wellness, but may
differ inasmuch as it focuses relatively more attention on
the practices and strategies that succeed in producing pos-
itive outcomes rather than upon the individual personal-
ity traits that contribute to resilience. Resilience, for
example, is more about personality traits and the effects of
external social factors such as social support and involve-
ment in activities [21-23]) whereas Positive Deviance is
more about strategies and practices that are protective.
Positive deviance approaches in HIV research have
focused on studying individual-level factors associated
with the absence of risk behaviors. Save the Children Fed-
eration conducted focus groups among Vietnamese IDUs
and commercial sex workers to elicit specific ways in
which they try to minimize their risks [24]. For IDUs, the
specific practices identified were (1) using a syringe only
if it was sealed in the package; (2) bending the needle after
use to prevent re-use; (3) telling those who asked that they
could not share needles because it could make them ill;
(4) getting syringes at a reduced rate at a pharmacy; and
(5) sniffing drugs rather than injecting if no clean syringe
was available. For sex workers, approaches identified were
(1) successfully negotiating condom use by telling clients
that she was concerned about their family getting ill; (2) if
no condom was readily available, telling the customer
that she wanted to put on something more attractive for
him–while asking a co-worker to go to the pharmacy and
buy condoms; and (3) asking if there was a particular type
of condom that a customer would like to use, and, if this
was not available, stating that they should use what was
available, but next time they would have their preferred
brand.
Babalola studied current lower risk behavior among
Rwandan youth as positive deviance [25]. Factors related
to sexual abstinence include non-urban residence,
younger age, Christian religion, not using alcohol, percep-
tions about peers' sexual behaviors, self-esteem, perceived
self-efficacy to refuse sex with someone known for more
than 3 months, perceived self-efficacy to refuse sex with
someone truly loved and attitudes toward premarital sex.
Thus in this study as in a study of West African youth [26],
they focus on beliefs, values, and support in the recent
past.
These studies focus on identifying safer behaviors or tac-
tics to negotiate safer behaviors and/or the relatively
immediate factors associated with safer behaviors. This is,
of course, extremely useful, and is quite parallel to innu-
merable studies of risk and non-risk in the HIV and HCV
fields. It is important to understand the difference
between these studies of positive deviance and those
which we are discussing in this paper. As opposed to their
primary emphasis on immediate or recent behaviors, our
methodology studies how some IDUs remain uninfected
over many years of injection drug use. Thus, our emphasis
is in terms of long-term trajectories in strategies, condi-
tions, practices, and events that shape sustained, long-
term safer behavior and/or long-term safer networks. This
requires more detailed data covering long time periods,BMC Public Health 2008, 8:94 http://www.biomedcentral.com/1471-2458/8/94
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including issues such as how they react when friends or
family go to or return from prison, get sick, or die.
Research methodologies such as the focus groups used by
Save the Children Federation in Vietnam are a good way
to elicit tactics. To discover and understand strategies,
however, requires the more in-depth life history method-
ologies we use.
Methods
The essential methodology is to recruit a group of controls
who have seemingly been at risk for a long period without
becoming infected and to compare it to an appropriate
comparison group of cases who have been infected. An
important component of this research is thus to find study
sites and subjects for whom having remained uninfected
is indeed an accomplishment; in practice, this means
looking at data on infection markers by years of potential
exposure.
Since the focus of this method is to explore ways in which
those at risk run their lives so as to remain uninfected, it is
important to minimize the probability that the negative
controls have remained uninfected for biological reasons
such as having immunity of a kind that does not show up
on standard assays. One way to do this is to focus on more
than one infection at a time. Thus, in New York we are
studying how IDUs remain uninfected with both HIV and
HCV by comparing these IDUs to those who are infected
with both and those who are infected only with HCV.
(The proportion that is infected only with HIV is quite
small, and is more likely to reflect biological causation.)
Although the fact that HIV prevalence among IDUs at this
time is "only" 19% [27] reduces the value of HIV negativ-
ity as a way to rule out low biological susceptibility to hep-
atitis C seroconversion, Aitken et al., (2004) [28] have
found a very low probability of falsely classifying subjects'
hepatitis C status due to clearing prior infection (but
remaining antibody-positive) or natural immunity. None-
theless, there may be a small proportion of injection drug
users who become exposed to hepatitis C but clear the
virus without becoming antibody positive [29,30], and
this does pose some risk of misclassification–and sup-
ports the importance of focusing on more than one infec-
tion where possible.
Figure 1 provides an overview of the processes that this
method addresses. Long-term risk avoidance involves
minimizing being in situations and engaging in behaviors
that pose a high risk of infection, and, when one is in a
high-risk situation, having a repertoire of methods to
avoid risk anyway. This means that the research focus is
on practices that are socially-embedded in one's social
network, as well as on how a person or small group of
people avoid or resist social pressures to take risk. We
want to learn from the experts–those who have avoided
infection–what they have done to stay safe, what they
have done for other reasons that has also helped them to
stay safe, how they learned to act in these ways, and how
they managed to maintain relatively safe behavior over a
period of many years while engaging in behaviors (drug
injection, selling sex) that, on the surface, seem to pose a
high risk of leading to infection.
Recruiting the participants and eligibility issues
The logic of the project requires that participants will have
been at risk (in this case, injecting drugs) long enough for
most of their cohort to have become infected with one or
both of the infectious agents being studied. A second com-
ponent to this logic may be less obvious–the value of an
upper bound on the exposure time for eligibility. This
upper bound serves two primary substantive functions.
The first is that we are generally going to try to understand
how people stay safe under more or less current condi-
tions, so we want to restrict the time period to a period in
which conditions have been more or less similar. For New
York, syringe exchange on a large scale began about 15
years before the project began gathering data, and this
greatly reduced the difficulties of obtaining sterile injec-
tion equipment. The second reason an upper bound is
useful is that it may restrict the effects of mortality upon
the sample of infected participants. People who are
infected with HIV (particularly if they are also infected
with hepatitis C) had a very high mortality rate before the
late 1990s–but this mainly became true more than five
years after they became infected. Thus, for IDUs in New
York, our criterion of recruiting IDUs with 8 – 15 years of
injection experience (with interviews beginning in 2005)
meant that they had all begun injecting after syringe
exchange opened; had mainly injected after the subse-
quent great decline in incidence rates [31], and would
have been very unlikely to have become infected early
enough to have died before HAART became widely used.
Finally, these criteria would recruit a sample of double-
negatives who were positive deviants since only 25% of
New York City IDUs in a reasonably representative detox
treatment entry sample who had been injecting for 8 – 15
years remained both HIV and HCV negative [13].
Similar patterns of reasoning motivated colleagues in Aus-
tralia and in England to propose 8 – 15 years of injecting
as their sampling frame for studies of how IDUs there had
remained uninfected with hepatitis C [13].
Since we are deliberately seeking out positive deviants (a
relatively rare group) as half of our overall sample, there
is considerable cost saving in studying subjects who are
referred to us by research or other sites who themselves do
the appropriate testing for HIV and hepatitis C antibody
and also screen subjects by how long they have been
injecting drugs. On the other hand, this has led to slowBMC Public Health 2008, 8:94 http://www.biomedcentral.com/1471-2458/8/94
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recruitment when these sites have other priorities, and
also limits our sample to those who use the sites.
Two sources recruited the subjects included in this paper:
First, the Risk Factors project at Beth Israel Medical Center
detoxification center, which has been the subject of many
research papers [27,31] was the referral source for five
subjects who were negative for both viruses, one who was
positive for both viruses, and two who were positive only
for hepatitis C. No one they approached to take part in the
Staying Safe Project told them that they would not partic-
ipate or refused to provide them with information about
how we could reach them. However, since some time
elapsed before antibody test results became available, it
was not always possible to reach potential subjects to
schedule an interview. This may have resulted in our sam-
ple under-recruiting IDUs with unstable lives. HIV testing
was conducted at the New York City Department of
Health Laboratory using repeated enzyme-linked immu-
nosorbent assays (ELISA) testing with Western blot confir-
mation. Hepatitis C testing there used Abbott HCV EIA
2.0 (Hepatitis C Virus encoded Antigen (Recombinant
c100-3, HC-31, andHC-34); confirmatory testing (RIBA
HCV 3.0 SIA) was performed when absorbance values
were equal to or less than 3.8: Chiron RIBA HCV 3.0 SIA
(Hepatitis C Virus encoded antigen (Recombinant c33c
and NS5 antigens;Synthetic 5-1-1, c100 and c22 pep-
tides).
Second, the Etiology of Bloodborne Viral Iinfections
project used respondent-driven sampling to recruit a rela-
tively representative sample of injectors, and referred
those meeting our criteria to us for interview. All eligible
subjects whom they referred were interviewed. It was the
referral source for twelve subjects who were negative for
both viruses, two who were positive for both viruses, and
three who were positive only for hepatitis C. Their sera
were screened for anti-HCV with a third generation
enzyme immunoassay (Abbott Laboratories, Chicago, Illi-
nois); and anti-HIV testing was performed using licensed
ELISA screening and western blot confirmatory tests.
Eliciting interview data
To elicit such data, we engage in a combination of ques-
tions that help us understand their overall biography and
the threats and resources this has involved; their history of
risk and risk avoidance; and detailed elicitation of some of
the key concepts presented in Figure 1.
Eliciting biographical information
Life histories are elicited in a two-step process. First, we
work with the participant to draw a visual timeline to
serve us as a schematic reminder of the participant's over-
all life and, equally or more important, to serve as an eas-
ily-accessible reference during the remainder of the
interview. (We enter this into TimeLine software after the
interview since doing it during the interview is cumber-
some and disrupts the natural flow of a person's describ-
ing her or his life.) An example of such a timeline appears
as Figure 2.
These timeline diagrams provide a valuable resource in
analysis that helps us identify patterns in the life history
data such as the relatively large number of years it took
some subjects between starting to inject and beginning to
use needle exchange.
After this, we interview the subject with a more detailed
biographically-structured interview guide (see Additional
file 1) that elicits narrative about their history and experi-
ences with drug use, access to drugs, sexual experiences
and relationships, institutional experience (including
medical history, hospitalization, incarceration and similar
issues), knowledge and practices of HIV and hepatitis C
and related issues, and strategies and tactics to avoid
stigma, high risk situations, and infection.
Eliciting additional information about protective tactics, strategies 
and environments
During this interview, and particularly at the end of it, as
well as in follow-up interviews, we try to understand the
social processes that lead to these tactics, strategies and
behaviors. Issues here include:
1.  Practices versus behaviors: Probes about the extent to
which particular behaviors or behavioral patterns are
socially-embedded practices or are more individualized
behaviors. This is not easy interviewing, because there is a
strong tendency in the drug culture as well as in the society
as a whole [32] to describe one's behaviors as expressions
of one's personality and choices. One approach we take to
probing this is to ask them about how they learned to do
things that way–since one perspective on culture is that it
consists largely of learned behavior. Another approach is
to ask them about how others would react if they behaved
in other ways, which gets at the processes by which norms
are maintained [33-37]
2. Indigenous prevention tactics: One of our goals is to iden-
tify indigenous prevention tactics–that is, behavioral rules
of thumb or practices which help subjects control their
risk that have immediate face validity as possible preven-
tion messages. These differ from trajectories, resources,
and strategies in that they are immediate and do not nec-
essarily address the issue of long-term maintenance of
safer practices (including maintaining indigenous preven-
tion tactics).
3. Strategic action: To determine whether a subject's partic-
ular pattern of action is strategic (i.e., planned and inten-BMC Public Health 2008, 8:94 http://www.biomedcentral.com/1471-2458/8/94
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Example of a Time Line for a Participant Figure 2
Example of a Time Line for a Participant. The participant is a white 33 year old woman who is HIV-negative and HCV-
negative. She has been injecting 13 years.
Category Color 
Criminal 
Justice/Criminalization    
Drug Use    
Injection     
Education    
Hospitalization/Medical 
Condition    
Living    
Memorable Event    
Needle Source and 
Syringe exchange    
Relationship/Bonds    
Sex    
Testing    
Drug Treatment    
Work    
Injection    
Mismatch of intake 
needs and drug 
availability    
Devolution    
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tional), we probe about why they engaged in the pattern
of action; the extent to which they planned it out; what
they had in mind; whether it emerged out of group discus-
sions, and if so, what the group was trying to accomplish
if anything. Given the frequently-changing situations
IDUs find themselves in, particularly in those periods of
their lives when they are street users, they sometimes have
trouble recognizing the extent to which their actions
indeed are based on planning and intentionality rather
than being overwhelmingly circumstantial and reactive.
We have uncovered some of their strategies in these cir-
cumstances by asking them how they apply their princi-
ples of infection avoidance, for example, to different
circumstances they face; and asking them to comment of
how and why they sometimes act differently in various cir-
cumstances from how those with them act.
Personality data about traits
One possible explanation for why some IDUs might be
able to remain uninfected would be if they share some
common personality trait or traits that remain reasonably
constant over the many years they have been injecting
drugs. To test for this, we use selected parts of the NEO PI-
R questionnaire. This questionnaire is based on Costa &
McCrae's Five Factor Model of Personality (FFM), which is
a highly influential theory of personality. It provides a rel-
atively comprehensive taxonomy of individual differ-
ences. The five domains are Neuroticism, the tendency to
experience negative affect (e.g., anxiety, depression, and
hostility); Extraversion, the quantity and intensity of inter-
personal interactions; Openness to Experience, seeking and
appreciation of new experiences; Agreeableness, the quality
of interpersonal interactions along a continuum from
compassion to antagonism; and Conscientiousness, the
amount of persistence, organization, and motivation in
goal-directed behaviors [38,39]. These factors show
extraordinary stability over time in normal populations,
with little change over decades [39,40] (The NEO PI-R
contains 240 items. It can be completed in 30 – 40 min-
utes).
Interview Contexts
Interviews were conducted under confidentiality and
other protocols approved by the institutional review
board of NDRI at a storefront field site located within a
few blocks of one referral site; another source referred par-
ticipants to us from several locations (including one in
which they rented space in a separate part of our store-
front). The different sections of the interviews took, on
average: 55 minutes for the Time Line; 81 minutes for the
detailed interview about protective strategies and related
matters in the context of their life history; and, in seven
cases when follow-up interviews have been conducted to
elicit more information about these topics, with special
attention to strategies and to the sharing of equipment
other than syringes, approximately another 80 minutes.
Participants are reimbursed $40 for their time and trouble
for the first interview and $30 for any subsequent inter-
views.
Analyzing the data to develop grounded hypotheses
Data analysis follows fairly standard techniques from
grounded theory and life history methodologies. All inter-
views are taped and transcribed. The transcripts are then
coded by both of the field staff using a combination of
theory-based and emergent coding categories [17], who
also discussed and resolved differences in coding. The
Principal Investigator read selected transcripts as well.
Discussions during project meetings helped new concepts
to emerge; there were often concepts that were more
abstract or process-oriented than those that emerged dur-
ing the coding itself. As staff developed ideas about
important processes, categories, or concepts, they wrote
and circulated theory notes for further discussion by
project members.
Due to difficulty recruiting infected subjects during the
early months of the project, the first set of emergent codes
were dominated by the materials from subjects who had
remained uninfected–that is, from those who had success-
fully "stayed safe." Later, as we interviewed IDUs who had
been infected with HCV and in some cases also with HIV,
categories began to emerge that reflect their lives and, use-
fully, the comparisons between the positives and the neg-
atives. Additional analyses may be conducted comparing
those who are infected with both HIV and HCV with those
who are infected with HCV but not HIV.
These categories and concepts are partially reflected in the
hypotheses presented in the Results section below. Since
both data collection and analysis are ongoing in this
project, we anticipate that additional grounded hypothe-
ses will be developed and those presented here may be
modified.
Results
Since this paper is primarily methodological, we simply
list here some of the hypotheses we have developed based
on interviews so far with 25 IDUs, of whom 17 were dou-
bly-uninfected, 3 doubly-infected, and 5 infected with
HCV but not with HIV. Several themes and initial hypoth-
eses have emerged from the data.
First, we propose two master hypotheses that, if con-
firmed, should be taken into account in forming preven-
tive interventions:
1. Staying uninfected is not simply a question of social
structure or social position. It involves agency on the part
of IDUs as well. Thus, it is not simply well-to-do IDUsBMC Public Health 2008, 8:94 http://www.biomedcentral.com/1471-2458/8/94
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who can avoid risk. Many IDUs whom we interviewed
remained uninfected with either HIV or HCV in spite of
five years or more of homelessness, arrests, exposure to
violence, and serious poverty; though a few of our unin-
fected IDUs had started out relatively well off and still
remain so. Thus, to a large extent, IDUs have agency, and
remaining uninfected is a result of considerable sustained
hard work and adaptation to changing circumstances.
2. Multiple "intentionalities" are hypothesized to help
contribute to remaining uninfected. Developing success-
ful ways to maintain a balance between one's need for
drugs and one's income, and in other ways to insure
access to drugs, is one dimension of this. Another is devel-
oping ways to stave off drug withdrawal sickness which is
an extremely unpleasant experience that drug users will
do much to avoid (and that also, as a result, poses a
heightened probability of engaging in behaviors that risk
infection). A third is trying to avoid situations in which
other drug users will importune you to share drugs. A
fourth is trying to avoid infection with HIV. A fifth, which
in many but not all localities is secondary to HIV-avoid-
ance [41] is avoiding infection with hepatitis C. An impor-
tant implication of this hypothesis should be noted: This
hypothesis means that focusing on a single goal in preven-
tion might be a sub-optimal approach. Individual-level
focused interventions that use cognitive-behavioral pro-
grams like the AIDS Risk Reduction Model [42], Health
Belief Model [43], Information-Motivation-Behavioral
Skills [44], Social Cognitive Theory [45,46], Social Action
Theory [47], Theory of Planned Behavior [48,49], and
Transtheoretical model [50-52] may be less effective than
programs that address more than one, or all, of the above
dimensions of intentionality.
In addition, we hypothesize that the following more spe-
cific practices, strategies and other characteristics of IDUs
form part of a complex and changing (as their lives
change) set of adaptive repertoires and other responses
and conditions that help keep IDUs uninfected:
1. Developing ways to avoid "drug sickness" (withdrawal)
by keeping drug need commensurate with money and
drugs availability such as maintaining close relationships
with drug dealers so they will lend you drugs; being a mid-
level dealer oneself; or using detoxification programs to
manage one's "habit."
2. Developing ways to ameliorate or to cope with drug
sickness episodes without engaging in high-risk injecting.
These methods seem to include planning ahead or devel-
oping social partnerships so you get sterile syringes,
whether from syringe exchanges, pharmacies, or diabetics
(both when in the community and when incarcerated);
sniffing drugs rather than injecting them when caught
without a sterile syringe; and going cold turkey without
drugs until they can get a clean syringe and finding ways
to distract themselves from their discomfort.
3. Developing ways to reduce peer pressure to share drugs
or equipment such as teaching lovers and friends to save
"wake-up bags"; injecting alone or with a like-minded
partner; and teaching and reinforcing safety practices in
one's own injection network.
4. Developing ways to handle stigma and to avoid "social
death." These include avoiding being identified by family,
friends or neighbors as an injector; using harm reduction
programs as sources of social support and friendship; and
never violating the space or property of some friends and
relatives so they will remain resources as a place to keep
papers, shower and/or sleep occasionally.
Discussion and Conclusion
We have identified strategies, tactics and practices that we
hypothesize have helped some IDUs remain both HIV-
negative and HCV-negative over 8 to 15 year long injec-
tion careers. Clearly, as indicated by Figure 1, these strate-
gies, tactics and practices take place in a probabilistic
environment. Thus, some IDUs have remained doubly-
uninfected even though they sometimes share syringes.
Others seem to have become infected with hepatitis C
from single instances of high-risk injection. This is sug-
gested by two subjects for whom we have two sets of test
results a few months apart; in each case, interviewing
them about what happened identified specific instances
of syringe sharing that we quite unusual and contra-nor-
mative for them.
They also take place in an environment in which one
potential structural limitation on the ability of IDUs has
been greatly reduced. This is syringe availability. Unlike
the circumstances during the early years of the epidemic in
New York, sterile syringes are now legally accessible and
comparatively plentiful.
Some (but not all) of these staying safe techniques, such
as controlling withdrawal and maintaining good sources
of drugs, were previously pointed to as strategies that had
been engaged in by long-time injectors who had survived
into their 50's [53]. Although these findings remain tenta-
tive, and may vary to some extent depending on the drugs
being used and variations in drug markets, we do think
they point the way to potentially-improved prevention
approaches and perhaps even a new generation of pro-
grams to help IDUs make their injection and sexual
careers safer for themselves and others. Since researchers
in Spain, Australia, the Czech Republic and England are
adapting Staying Safe methodology to study long-term
HCV and/or HIV avoidance; collaboration among us willBMC Public Health 2008, 8:94 http://www.biomedcentral.com/1471-2458/8/94
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widen our ability to learn about and disseminate success-
ful innovations and to understand the implications of dif-
ferent patterns of drug use (such as the proportions of
injectors who mainly inject heroin versus atimulants) on
the hypothoses that are developed.
Methodologically
Staying Safe methodology helps develop grounded
hypotheses about how outwardly-high-risk people
remain uninfected.
Hypothesis-testing
Such hypotheses of course need to be verified epidemio-
logically through cohort studies of incidence and/or
through prevention trials that test these hypotheses
together with testing ways to apply them in practice.
The positive deviance control-case life history method
should be applicable to studying ways in which people
remain safe from other infections like genital herpes
among sex workers. Indeed, we suspect it may provide a
mechanism to discover new ways to prevent a variety of
highly-prevalent infectious diseases, and perhaps behav-
ioral disorders that have proven resistant to existent tech-
niques.
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